Novel treatment strategies for malignant melanoma : A new beginning?KASPER, Bernd; D'HONDT, Veronique; VEREECKEN, Pierre et al.Critical reviews in oncology/hematology. 2007, Vol 62, Num 1, pp 16-22, issn 1040-8428, 7 p.Article

Hautveränderungen durch targeted therapies bei onkologischen Patienten : Kutane Nebenwirkungen zielgerichteter Therapie bei onkologischen Patienten = Skin changes as a result of targeted therapies in oncology patients ·Cutaneous side effects of targeted therapies in oncology patientsKÄHLER, K. C; HAUSCHILD, A.Der Hautarzt. 2009, Vol 60, Num 5, pp 433-439, issn 0017-8470, 7 p.Article

Mast cells and cancer-No longer just basic scienceGALINSKY, Daliah Shoshana Tamar; NECHUSHTAN, Hovav.Critical reviews in oncology/hematology. 2008, Vol 68, Num 2, pp 115-130, issn 1040-8428, 16 p.Article

Biology and management of relapsed acute myeloid leukaemiaCRADDOCK, Charles; TAURO, Sudhir; MOSS, Paul et al.British journal of haematology. 2005, Vol 129, Num 1, pp 18-34, issn 0007-1048, 17 p.Article

Novel therapies for myelodysplastic syndromesFADERL, Stefan; KANTARJIAN, Hagop M.Cancer. 2004, Vol 101, Num 2, pp 226-241, issn 0008-543X, 16 p.Article

Current treatments and promising investigations in a multidisciplinary settingVOKES, E.Annals of oncology. 2005, Vol 16, pp vi25-vi30, issn 0923-7534, SUP6Conference Paper

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directionsGUALBERTO, A; POLLAK, M.Oncogene (Basingstoke). 2009, Vol 28, Num 34, pp 3009-3021, issn 0950-9232, 13 p.Article

Current therapeutic strategies for acute myeloid leukaemiaKOLITZ, Jonathan E.British journal of haematology. 2006, Vol 134, Num 6, pp 555-572, issn 0007-1048, 18 p.Article

A review of tumour lysis syndrome with targeted therapies and the role of rasburicaseBOSE, P; QUBAIAH, O.Journal of clinical pharmacy and therapeutics (Print). 2011, Vol 36, Num 3, pp 299-326, issn 0269-4727, 28 p.Article

Investigator-initiated trials of targeted oncology agents: why independent research is at risk?BERGMANN, L; BERNS, B; ZWIERZINA, H et al.Annals of oncology. 2010, Vol 21, Num 8, pp 1573-1578, issn 0923-7534, 6 p.Article

Current Adjuvant and Targeted Therapies for Pancreatic AdenocarcinomaSANCHEZ, Sabrina E; TREVINO, Jose G.Current medicinal chemistry. 2008, Vol 15, Num 17, pp 1674-1683, issn 0929-8673, 10 p.Article

Molecular targets in melanoma : Strategies and challenges for diagnosis and therapyHERLYN, Meenhard.International journal of cancer. 2006, Vol 118, Num 3, pp 523-526, issn 0020-7136, 4 p.Article

Epigenetics and OncologyMUMMANENI, Padmaja; SHORD, Stacy S.Pharmacotherapy. 2014, Vol 34, Num 5, pp 495-505, issn 0277-0008, 11 p.Article

Immunseneszenz: Bestandsaufnahme und molekulare Grundlagen : Hautalterung/Anti-Aging-Strategien = Immunosenescence. Current status and molecular mechanisms : Skin Aging/Anti-aging StrategiesPETERS, T.Der Hautarzt. 2011, Vol 62, Num 8, pp 598-606, issn 0017-8470, 9 p.Article

Toxicity of targeted therapy: Implications for response and impact of genetic polymorphismsLIU, Sariah; KURZROCK, Razelle.Cancer treatment reviews. 2014, Vol 40, Num 7, pp 883-891, issn 0305-7372, 9 p.Article

Kutane Nebenwirkungen der medikamentösen Tumortherapie : Medikamentöse Tumortherapie in der dermatologie = Cutaneous side effects of medical tumor therapy : Medical tumor therapy in dermatologyDEGEN, A; ALTER, M; SCHENCK, F et al.Der Hautarzt. 2011, Vol 62, Num 6, pp 444-450, issn 0017-8470, 7 p.Article

Targeted therapy-induced radiation recallLEVY, Antonin; HOLLEBECQUE, Antoine; DEUTSCH, Eric et al.European journal of cancer (1990). 2013, Vol 49, Num 7, pp 1662-1668, issn 0959-8049, 7 p.Article

Targeting DNA repair mechanisms in cancerFURGASON, John M; EL MUSTAPHA BAHASSI.Pharmacology & therapeutics (Oxford). 2013, Vol 137, Num 3, pp 298-308, issn 0163-7258, 11 p.Article

Multitargeted therapy : Can promiscuity be praised in an era of political correctness?JIMENO, Antonio; HIDALGO, Manuel.Critical reviews in oncology/hematology. 2006, Vol 59, Num 2, pp 150-158, issn 1040-8428, 9 p.Article

Making efficient use of patients in designing phase III trials investigating simultaneously a set of targeted therapies with different targets. DiscussionVACH, Werner; DEPONT CHRISTENSEN, Rene; THOMPSON, Simon G et al.Biometrical journal. 2006, Vol 48, Num 6, pp 897-915, issn 0323-3847, 19 p.Article

Ciblage thérapeutique personnalisé par analyse d'exomes = Personalized therapeutic targeting by exome analysisLAMY, Aude; ANGOT, Emilie; SABOURIN, Jean-Christophe et al.Annales de pathologie (Print). 2012, Vol 32, issn 0242-6498, S44-S45, HS1Conference Paper

Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis : Naturally Occuring Molecules and Anticancer Combination Therapies in the Era of Personalized Medicine and Economic CrisisMANARA, Maria Cristina; GAROFALO, Cecilia; FERRARI, Stefano et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 30, pp 5344-5361, issn 1381-6128, 18 p.Article

Change in prognostic factorsHOELZER, D; GÖKBUGET, N.Leukemia supplements (Print). 2012, Vol 1, Num 2, issn 2044-5210, S1-S2Conference Paper

Neuropilin-1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodellingBERGE, Mathieu; ALLANIC, David; LEVY, Bernard I et al.Journal of hepatology. 2011, Vol 55, Num 4, pp 866-875, issn 0168-8278, 10 p.Article

Improving the outcome of patients with castration-resistant prostate cancer through rational drug developmentATTARD, G; SARKER, D; REID, A et al.British journal of cancer. 2006, Vol 95, Num 7, pp 767-774, issn 0007-0920, 8 p.Article